These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 3436739

  • 1. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.
    Harrison SD, Brockman RW, Trader MW, Laster WR, Griswold DP.
    Invest New Drugs; 1987 Dec; 5(4):345-51. PubMed ID: 3436739
    [Abstract] [Full Text] [Related]

  • 2. Antitumor spectrum of deoxyspergualin and its lack of cross-resistance to other antitumor agents.
    Nishikawa K, Shibasaki C, Hiratsuka M, Arakawa M, Takahashi K, Takeuchi T.
    J Antibiot (Tokyo); 1991 Oct; 44(10):1101-9. PubMed ID: 1955393
    [Abstract] [Full Text] [Related]

  • 3. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
    Harrison SD, Plowman J, Dykes DJ, Waud WR, Griswold DP.
    Cancer Chemother Pharmacol; 1990 Oct; 25(6):425-9. PubMed ID: 2311170
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
    Waud WR, Plowman J, Harrison SD, Dykes DJ, Anderson WK, Griswold DP.
    Cancer Chemother Pharmacol; 1992 Oct; 30(4):261-6. PubMed ID: 1322803
    [Abstract] [Full Text] [Related]

  • 5. PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.
    Yagi MJ, Chin SE, Scanlon KJ, Holland JF, Bekesi JG.
    Biochem Pharmacol; 1985 Jul 01; 34(13):2347-54. PubMed ID: 4040366
    [Abstract] [Full Text] [Related]

  • 6. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
    Waud WR, Harrison SD, Gilbert KS, Laster WR, Griswold DP.
    Cancer Chemother Pharmacol; 1991 Jul 01; 27(6):456-63. PubMed ID: 1849465
    [Abstract] [Full Text] [Related]

  • 7. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP, Trader MW, Frei E, Peters WP, Wolpert MK, Laster WR.
    Cancer Res; 1987 May 01; 47(9):2323-7. PubMed ID: 3567926
    [Abstract] [Full Text] [Related]

  • 8. Antitumor activity of spergualin, a novel antitumor antibiotic.
    Nishikawa K, Shibasaki C, Takahashi K, Nakamura T, Takeuchi T, Umezawa H.
    J Antibiot (Tokyo); 1986 Oct 01; 39(10):1461-6. PubMed ID: 3781914
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.
    Waud WR, Harrison SD, Temple CG, Griswold DP.
    Cancer Chemother Pharmacol; 1992 Oct 01; 29(3):190-4. PubMed ID: 1733551
    [Abstract] [Full Text] [Related]

  • 12. Reversal of doxorubicin and cisplatin resistance in vivo in murine leukemias by the calcium antagonist RO 11-2933.
    Mazzoni A, Canti G.
    Sel Cancer Ther; 1990 Oct 01; 6(4):167-76. PubMed ID: 2094936
    [Abstract] [Full Text] [Related]

  • 13. Inability of amphotericin B(Fungizone) or of sodium deoxycholate to alter natural drug resistance or sensitivity of transplanted murine leukemias.
    Ganu UK, Khandalekar DD, Gokhale SV.
    Indian J Physiol Pharmacol; 1984 Oct 01; 28(1):21-6. PubMed ID: 6490126
    [Abstract] [Full Text] [Related]

  • 14. [Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia].
    Nakajima T, Masuda H, Okamoto T, Watanabe M, Yokoyama K, Yamada N, Fujimoto S, Tsukagoshi S, Taguchi T.
    Gan To Kagaku Ryoho; 1991 Feb 01; 18(2):201-9. PubMed ID: 1899547
    [Abstract] [Full Text] [Related]

  • 15. [Models of preclinical studies of anthracyclines].
    Fizames C.
    Pathol Biol (Paris); 1987 Jan 01; 35(1):41-8. PubMed ID: 3550611
    [Abstract] [Full Text] [Related]

  • 16. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
    Garibjanian BT, Johnson RK, Kline I, Vadlamudi S, Gang M, Venditti JM, Goldin A.
    Cancer Treat Rep; 1976 Sep 01; 60(9):1347-61. PubMed ID: 797450
    [Abstract] [Full Text] [Related]

  • 17. Induction of antitumor resistance to mouse leukemia L1210 by spergualins.
    Ishizuka M, Masuda T, Mizutani S, Osono M, Kumagai H, Takeuchi T, Umezawa H.
    J Antibiot (Tokyo); 1986 Dec 01; 39(12):1736-43. PubMed ID: 3546237
    [Abstract] [Full Text] [Related]

  • 18. Combination of 5-fluorouracil and cyclophosphamide in L1210 and P388 leukemias with changes in optimum treatments as a function of the age of the L1210 tumor at first treatment.
    Wampler GL, Carter WH, Campbell ED.
    Cancer Invest; 1987 Dec 01; 5(6):523-33. PubMed ID: 3442730
    [Abstract] [Full Text] [Related]

  • 19. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
    Schmid FA, Otter GM, Stock CC.
    Cancer Res; 1980 Mar 01; 40(3):830-3. PubMed ID: 7471099
    [Abstract] [Full Text] [Related]

  • 20. Effect of 3'-amino-3'-deoxythymidine on L1210 and P388 leukemias in mice.
    Lin TS, Fischer PH, Prusoff WH.
    Biochem Pharmacol; 1982 Jan 01; 31(1):125-8. PubMed ID: 7059345
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.